April 20, 2017


Can Cholesterol Drug Sponsors Make the Case for Statin Intolerance?

By Mary Jo Laffler

Amgen’s FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.

read full article >